Published in J Leukoc Biol on January 01, 2006
Sepsis-induced inhibition of neutrophil chemotaxis is mediated by activation of peroxisome proliferator-activated receptor-{gamma}. Blood (2008) 1.12
Peroxisome proliferator-activated receptor gamma1 expression is diminished in human osteoarthritic cartilage and is downregulated by interleukin-1beta in articular chondrocytes. Arthritis Res Ther (2007) 1.06
New insights into the role of peroxisome proliferator-activated receptors in regulating the inflammatory response after tissue injury. PPAR Res (2012) 0.94
Regulation of Lymphocyte Function by PPARgamma: Relevance to Thyroid Eye Disease-Related Inflammation. PPAR Res (2008) 0.90
Changes in peroxisome proliferator-activated receptor-gamma activity in children with septic shock. Intensive Care Med (2009) 0.88
Peroxisome proliferator-activated receptor gamma is required for CD4+ T cell-mediated lymphopenia-associated autoimmunity. J Immunol (2011) 0.83
Role of peroxisome proliferator-activated receptor gamma and its ligands in the treatment of hematological malignancies. PPAR Res (2008) 0.83
Alterations of dendritic cells in sepsis: featured role in immunoparalysis. Biomed Res Int (2015) 0.82
Novel Therapeutic Agents in Pediatric Sepsis: Peroxisome Proliferator Receptor γ (PPAR γ) Agonists. Open Inflamm J (2011) 0.80
The modulation of PPARγ1 and PPARγ2 mRNA expression by ciglitazone in CD3/CD28-activated naïve and memory CD4+ T cells. Clin Dev Immunol (2012) 0.79
Peroxisome Proliferator-Activated Receptor-γ-Mediated Polarization of Macrophages in Leishmania Infection. PPAR Res (2012) 0.79
PPARγ in Bacterial Infections: A Friend or Foe? PPAR Res (2016) 0.75
Peroxisome proliferator-activated receptor-γ agonist inhibits the mammalian target of rapamycin signaling pathway and has a protective effect in a rat model of status epilepticus. Mol Med Rep (2015) 0.75
Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med (2008) 19.93
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med (2013) 5.72
A Multicenter Trial of Remote Ischemic Preconditioning for Heart Surgery. N Engl J Med (2015) 4.22
Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: a retrospective observational study. Lancet (2008) 4.12
Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care (2013) 3.90
Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology (2012) 3.37
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol (2012) 2.97
Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med (2007) 2.97
Inhibition of GTP cyclohydrolase attenuates tumor growth by reducing angiogenesis and M2-like polarization of tumor associated macrophages. Int J Cancer (2012) 2.80
Practice and perception--a nationwide survey of therapy habits in sepsis. Crit Care Med (2008) 2.43
Rapid Diagnosis of Infection in the Critically Ill, a Multicenter Study of Molecular Detection in Bloodstream Infections, Pneumonia, and Sterile Site Infections. Crit Care Med (2015) 2.37
Acute renal failure in patients with severe sepsis and septic shock--a significant independent risk factor for mortality: results from the German Prevalence Study. Nephrol Dial Transplant (2007) 2.25
Role of kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovascularization potential. Circ Res (2008) 2.12
Nitric oxide impairs normoxic degradation of HIF-1alpha by inhibition of prolyl hydroxylases. Mol Biol Cell (2003) 2.11
Tumor hypoxia and cancer progression. Cancer Lett (2005) 1.87
Bacterial DNA induces myocardial inflammation and reduces cardiomyocyte contractility: role of toll-like receptor 9. Cardiovasc Res (2008) 1.80
Preconditioning by toll-like receptor 2 agonist Pam3CSK4 reduces CXCL1-dependent leukocyte recruitment in murine myocardial ischemia/reperfusion injury. Crit Care Med (2010) 1.73
September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist (2008) 1.71
The fibrin-derived peptide Bbeta15-42 protects the myocardium against ischemia-reperfusion injury. Nat Med (2005) 1.66
AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study. J Hypertens (2002) 1.63
The fibrin-derived peptide Bbeta15-42 is cardioprotective in a pig model of myocardial ischemia-reperfusion injury. Crit Care Med (2007) 1.61
Bbeta15-42 (FX06) reduces pulmonary, myocardial, liver, and small intestine damage in a pig model of hemorrhagic shock and reperfusion. Crit Care Med (2009) 1.54
Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. J Hypertens (2011) 1.51
Comments on Reinhart et al.: consensus statement of the ESICM task force on colloid volume therapy in critically ill patients. Intensive Care Med (2012) 1.47
Toll-like receptor 2 signaling triggers fatal arrhythmias upon myocardial ischemia-reperfusion. Crit Care Med (2010) 1.45
Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size. Shock (2010) 1.44
MicroRNA-27b contributes to lipopolysaccharide-mediated peroxisome proliferator-activated receptor gamma (PPARgamma) mRNA destabilization. J Biol Chem (2010) 1.44
Determination of organ-specific anemia tolerance. Crit Care Med (2013) 1.42
Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. Kidney Int (2002) 1.41
Impact of NO-synthase inhibition on renal hemodynamics in normotensive and hypertensive subjects. J Hypertens (2002) 1.41
Apoptotic cells promote macrophage survival by releasing the antiapoptotic mediator sphingosine-1-phosphate. Blood (2006) 1.40
Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary. Onkologie (2009) 1.40
Redox control of inflammation in macrophages. Antioxid Redox Signal (2013) 1.39
Heme oxygenase-1 contributes to an alternative macrophage activation profile induced by apoptotic cell supernatants. Mol Biol Cell (2009) 1.31
Tumor cell apoptosis polarizes macrophages role of sphingosine-1-phosphate. Mol Biol Cell (2007) 1.30
Novel aspects of fibrin(ogen) fragments during inflammation. Mol Med (2011) 1.30
Tumor necrosis factor-alpha causes accumulation of a ubiquitinated form of hypoxia inducible factor-1alpha through a nuclear factor-kappaB-dependent pathway. Mol Biol Cell (2003) 1.30
Nitric oxide, apoptosis and macrophage polarization during tumor progression. Nitric Oxide (2008) 1.26
HIF-1 in the inflammatory microenvironment. Exp Cell Res (2009) 1.25
PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation. J Biol Chem (2004) 1.25
Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". J Dtsch Dermatol Ges (2013) 1.25
Re-evaluating currently available data and suggestions for planning randomised controlled studies regarding the use of hydroxyethyl starch in critically ill patients - a multidisciplinary statement. Crit Care (2013) 1.24
Global spread of New Delhi metallo-β-lactamase 1. Lancet Infect Dis (2010) 1.24
HIF-1 and p53: communication of transcription factors under hypoxia. J Cell Mol Med (2004) 1.20
Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens (2002) 1.19
p300 relieves p53-evoked transcriptional repression of hypoxia-inducible factor-1 (HIF-1). Biochem J (2004) 1.19
HIF-1 alpha protein as a target for S-nitrosation. FEBS Lett (2003) 1.17
Sphingosine kinase 2 deficient tumor xenografts show impaired growth and fail to polarize macrophages towards an anti-inflammatory phenotype. Int J Cancer (2009) 1.17
The nuclear hormone receptor PPARγ as a therapeutic target in major diseases. ScientificWorldJournal (2010) 1.16
Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis? Biomarkers (2011) 1.16
Oxidized low-density lipoprotein (oxLDL) triggers hypoxia-inducible factor-1alpha (HIF-1alpha) accumulation via redox-dependent mechanisms. Blood (2003) 1.15
Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood (2002) 1.14
Roles of hypoxia-inducible factor-1alpha (HIF-1alpha) versus HIF-2alpha in the survival of hepatocellular tumor spheroids. Hepatology (2010) 1.13
Hypoxia enhances sphingosine kinase 2 activity and provokes sphingosine-1-phosphate-mediated chemoresistance in A549 lung cancer cells. Mol Cancer Res (2009) 1.13
Cytokines and hormones in the regulation of hypoxia inducible factor-1alpha (HIF-1alpha). Cardiovasc Hematol Agents Med Chem (2006) 1.10
PPARgamma1 attenuates cytosol to membrane translocation of PKCalpha to desensitize monocytes/macrophages. J Cell Biol (2007) 1.10
Hypoxia causes epigenetic gene regulation in macrophages by attenuating Jumonji histone demethylase activity. Cytokine (2010) 1.10
IFN-alpha skews monocytes into CD56+-expressing dendritic cells with potent functional activities in vitro and in vivo. J Immunol (2008) 1.09
Impaired adrenal stress response in Toll-like receptor 2-deficient mice. Proc Natl Acad Sci U S A (2004) 1.09
Influence of genetic variations in TLR4 and TIRAP/Mal on the course of sepsis and pneumonia and cytokine release: an observational study in three cohorts. Crit Care (2010) 1.08
Regulation of macrophage function by sphingosine-1-phosphate. Immunobiology (2009) 1.08
Role of sestrin2 in peroxide signaling in macrophages. FEBS Lett (2009) 1.08
Enhanced levels of platelet P-selectin and circulating cytokines in young patients with mild arterial hypertension. J Hypertens (2005) 1.08
Clinical chemistry reference database for Wistar rats and C57/BL6 mice. Biol Chem (2007) 1.08
Knockout of HIF-1α in tumor-associated macrophages enhances M2 polarization and attenuates their pro-angiogenic responses. Carcinogenesis (2010) 1.07
NO and TNF-alpha released from activated macrophages stabilize HIF-1alpha in resting tubular LLC-PK1 cells. Am J Physiol Cell Physiol (2002) 1.07
Reactive oxygen species attenuate nitric-oxide-mediated hypoxia-inducible factor-1alpha stabilization. Free Radic Biol Med (2006) 1.07
Activation of peroxisome proliferator-activated receptor gamma by nitric oxide in monocytes/macrophages down-regulates p47phox and attenuates the respiratory burst. J Immunol (2002) 1.06
Major confounders may influence multivariate analysis in a single-center observational study. Crit Care Med (2014) 1.06
Low-flow CO₂ removal integrated into a renal-replacement circuit can reduce acidosis and decrease vasopressor requirements. Crit Care (2013) 1.05
Inhibition of GSK3beta by indirubins restores HIF-1alpha accumulation under prolonged periods of hypoxia/anoxia. FEBS Lett (2005) 1.04
NO restores HIF-1alpha hydroxylation during hypoxia: role of reactive oxygen species. Free Radic Biol Med (2005) 1.04
Peptide Bbeta(15-42) preserves endothelial barrier function in shock. PLoS One (2009) 1.02
Peroxisome proliferator-activated receptor gamma as a molecular target of resveratrol-induced modulation of polyamine metabolism. Cancer Res (2006) 1.01
Inflammation-induced loss of Pdcd4 is mediated by phosphorylation-dependent degradation. Carcinogenesis (2011) 1.01
CpG oligonucleotide activates Toll-like receptor 9 and causes lung inflammation in vivo. Respir Res (2007) 1.00
miR-127 protects proximal tubule cells against ischemia/reperfusion: identification of kinesin family member 3B as miR-127 target. PLoS One (2012) 1.00
Cleavage of sphingosine kinase 2 by caspase-1 provokes its release from apoptotic cells. Blood (2010) 1.00
Priming with synthetic oligonucleotides attenuates pressure overload-induced inflammation and cardiac hypertrophy in mice. Cardiovasc Res (2012) 0.99
The NFKB1 promoter polymorphism (-94ins/delATTG) alters nuclear translocation of NF-κB1 in monocytes after lipopolysaccharide stimulation and is associated with increased mortality in sepsis. Anesthesiology (2013) 0.99
Redox mechanisms involved in the selective activation of Nrf2-mediated resistance versus p53-dependent apoptosis in adenocarcinoma cells. J Biol Chem (2009) 0.99
Efficacy of the EZ-IO needle driver for out-of-hospital intraosseous access--a preliminary, observational, multicenter study. Scand J Trauma Resusc Emerg Med (2011) 0.98
HIF-1alpha and p53 as targets of NO in affecting cell proliferation, death and adaptation. Curr Mol Med (2004) 0.98
Tranexamic acid partially improves platelet function in patients treated with dual antiplatelet therapy. Eur J Anaesthesiol (2011) 0.97
A23187, ionomycin and thapsigargin upregulate mRNA of HIF-1alpha via endoplasmic reticulum stress rather than a rise in intracellular calcium. J Cell Physiol (2008) 0.97
Calpain mediates a von Hippel-Lindau protein-independent destruction of hypoxia-inducible factor-1alpha. Mol Biol Cell (2006) 0.97
Anti-inflammatory role of microsomal prostaglandin E synthase-1 in a model of neuroinflammation. J Biol Chem (2010) 0.97
Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol (2013) 0.96
Critical role for classical PKC in activating Akt by phospholipase A2-modified LDL in monocytic cells. Cardiovasc Res (2006) 0.96
Erioflorin stabilizes the tumor suppressor Pdcd4 by inhibiting its interaction with the E3-ligase β-TrCP1. PLoS One (2012) 0.95